Search bioRxiv⌕ Search

Biology subjects

Strong, J.

Publications and source records attributed to Strong, J..

3 recordsLinked to original sources

Decoding Multicellular Communication Motifs from Spatial Transcriptomics with ALARMIST

Cellular organization is driven by recurrent, coordinated interactions between multiple cell types, each sending and receiving multiple signals. Existing computational methods for spatial profiling data consider only individual ligand-receptor interactions and fail to capture the higher-order interactions governing the tissue microenvironment. To address this gap, we developed ALARMIST (Assessment of Ligand And Receptor Motifs And Impacts in Spatial Transcriptomics), a probabilistic framework that infers interpretable multicellular communication patterns from spatial data. ALARMIST decomposes neighborhood-level signaling patterns into motifs: recurrent communication subnetworks involving multiple cell types and sets of enriched ligand-receptor interactions. For each cell, ALARMIST identifies its active motifs and estimates the downstream phenotypic effects of each motif on active cells. We applied alarmist to spatial datasets of lung adenocarcinoma (LUAD) and glioblastoma (GBM) to identify microenvironmental drivers of tumor progression. In paired LUAD and adenocarcinoma-in-situ (AIS) samples, ALARMIST identified an immune-active vascular motif at the tumor-normal boundary and implicated motif-active plasmacytoid dendritic cells as drivers of inflammation in early carcinogenesis. In matched low- and high-grade glioma samples, ALARMIST identified a hub-and-spoke motif centered on a malignant macrophage subpopulation, implicating a GRN-SORT1 signaling axis with a downstream impact gene set predictive of survival in low-grade glioma patients. Code for ALARMIST is available at https://github.com/tansey-lab/alarmist.

bioinformatics↗

ATP13A2 Loss of Function-Driven Polyamine Dysregulation Induces SAM Depletion and Epigenetic Astrocyte Toxicity

Aging is the strongest risk factor for neurodegeneration, yet how the human brain ages remains poorly understood. Loss-of-function (LOF) variants in ATP13A2 cause severe juvenile-onset Parkinsons disease, providing a window into the mechanisms that accelerate age-related neurodegeneration. ATP13A2-LOF causes lysosomal polyamine sequestration, but how this promotes pathogenesis remains unclear. We discovered that ATP13A2-LOF depletes cytosolic polyamines in astrocytes, triggering compensatory upregulation of de novo polyamine biosynthesis, which diverts S-adenosyl methionine (SAM) from DNA and histone methylation, leading to increased chromatin accessibility and epigenetic reprogramming of astrocytes into a neuroinflammatory state that releases neurotoxic cytokines that promote dopaminergic neuron death. In ATP13A2 knockout mice and human models, we find that genetic and pharmacological inhibition of SAM utilization in polyamine biosynthesis prevents astrocytic epigenetic reprogramming and promotes dopaminergic neuron survival. These findings reveal a direct link between polyamine metabolism, epigenetic dysfunction, and neurotoxic inflammation, uncovering new therapeutic opportunities in Parkinsons disease.

neuroscience↗

An S1 subunit vaccine and combination adjuvant (COVAC-1) elicits robust protection against SARS-CoV-2 challenge in African green monkeys

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the agent responsible for the ongoing global pandemic. With over 500 million cases and more than 6 million deaths reported globally, the need for access to effective vaccines is clear. An ideal SARS-CoV-2 vaccine will prevent pathology in the lungs and prevent virus replication in the upper respiratory tract, thus reducing transmission. Here, we assessed the efficacy of an adjuvanted SARS-CoV-2 S1 subunit vaccine, called COVAC-1, in an African green monkey (AGM) model. AGMs immunized and boosted with COVAC-1 were protected from SARS-CoV-2 challenge compared to unvaccinated controls based on reduced pathology and reduced viral RNA levels and infectious virus in the respiratory tract. Both neutralizing antibodies and antibodies capable of mediating antibody-dependent cell-mediated cytotoxicity (ADCC) were observed in vaccinated animals prior to the challenge. COVAC-1 induced effective protection, including in the upper respiratory tract, thus supporting further development and utility for determining the mechanism that confers this protection. AUTHOR SUMMARYVaccines that can prevent the onward transmission of SARS-CoV-2 and prevent disease are highly desirable. Whether this can be accomplished without mucosal immunization by a parenterally administered subunit vaccine is not well established. Here we demonstrate that following two vaccinations, a protein subunit vaccine containing the S1 portion of the SARS-CoV-2 spike glycoprotein and the novel adjuvant TriAdj significantly reduces the amount of virus in the lungs and also mediates rapid clearance of the virus from the upper respiratory tract. Further support of the effectiveness of COVAC-1 was the observation of reduced pathology in the lungs and viral RNA being largely absent from tissues, blood, and rectal swabs. Thus COVAC-1 appears promising at mediating protection in both the upper and lower respiratory tract and may be capable of reducing subsequent transmission of SARS-CoV-2. Further investigation into the mechanism of protection in the upper respiratory tract and the initial immune response that supports this would be warranted.

microbiology↗